1. P671 Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study. (25th January 2019) Authors: White, J R; Din, S; Ingram, R; Foley, S; Alam, M A; Robinson, R; Francis, R; Tucker, E; Jalal, M; Elphick, D; Atallah, E; Norman, A; Amin, M; Sajjad, A; Heggs, N; Meadowcroft, S; Moran, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn's disease in the UK and Ireland: OCTAVO cohort 2. (15th January 2020) Authors: Parkes, G; Akbar, A; Beales, I; Buckley, M; Creed, T; Din, S; Fraser, A; Plevris, N; Meadowcroft, S; Owen, G; Heggs, N Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S575 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PTH-134 Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the east midlands. (June 2019) Authors: White, JR; Din, S; Ingram, R; Foley, S; Alam, M; Robinson, R; Francis, R; Tucker, E; Jalal, M; Elphick, D; Atallah, E; Norman, A; Amin, M; Sajjad, A; Heggs, N; Meadowcroft, S; Moran, GW Journal: Gut Issue: Volume 68(2019)Supplement 2 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗